These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36752579)

  • 41. Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice.
    Haferkamp S; Alter M; Debus D; Schilling B; Pinter A; Terheyden P; Utikal JS; Sachse MM; Haalck T; Wolf IH
    Adv Ther; 2020 Aug; 37(8):3619-3629. PubMed ID: 32638206
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience from 2 Tertiary Referral Centers.
    Morellá Fernández M; Balsalobre Yago J; Martínez García J; Peláez Gutiérrez M; López Muñoz A; Silvestre Ballesta AI; Sánchez Lafuente B; Martínez Martín I; Cerezuela Fuentes P
    Actas Dermosifiliogr; 2024 Sep; ():. PubMed ID: 39271008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
    Luke JJ; Ghate SR; Kish J; Lee CH; McAllister L; Mehta S; Ndife B; Feinberg BA
    Future Oncol; 2019 Sep; 15(25):2933-2942. PubMed ID: 30799646
    [No Abstract]   [Full Text] [Related]  

  • 44. Adjuvant therapy for stage II melanoma: the need for further studies.
    Lee R; Mandala M; Long GV; Eggermont AMM; van Akkooi ACJ; Sandhu S; Garbe C; Lorigan P
    Eur J Cancer; 2023 Aug; 189():112914. PubMed ID: 37301717
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
    Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations.
    Koelblinger P; Hoellwerth M; Dernoscheg MT; Koch L; Richtig E; Wanner M; Nguyen VA; Ostermann H; Bauer JW; Laimer M
    J Dtsch Dermatol Ges; 2021 Aug; 19(8):1186-1198. PubMed ID: 34255435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.
    Atkinson V; Robert C; Grob JJ; Gogas H; Dutriaux C; Demidov L; Gupta A; Menzies AM; Ryll B; Miranda F; Banerjee H; Lau M; Del Vecchio M
    Eur J Cancer; 2022 Mar; 163():79-87. PubMed ID: 35042070
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.
    Mooradian MJ; Sullivan RJ
    Cancer; 2023 Jul; 129(14):2117-2121. PubMed ID: 37345669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation.
    Mulder EEAP; Smit L; Grünhagen DJ; Verhoef C; Sleijfer S; van der Veldt AAM; Uyl-de Groot CA
    ESMO Open; 2021 Dec; 6(6):100303. PubMed ID: 34781194
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma.
    Takahashi A; Namikawa K; Nakano E; Yamazaki N
    J Dermatol; 2020 Mar; 47(3):257-264. PubMed ID: 31876308
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field.
    Eljilany I; Castellano E; Tarhini AA
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
    J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.
    Egeler M; Lai-Kwon J; Tissier R; Fraterman I; Kuijpers A; Van Houdt W; Wilgenhof S; Rao A; Sandhu S; Lee R; Eriksson H; van Leeuwen M; de Ligt K; van Akkooi A; van de Poll-Franse L
    Eur J Cancer; 2024 Mar; 200():113601. PubMed ID: 38340383
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Failure of adjuvant treatment for malignant melanoma - what next?
    Žiaran M; Dvořák P; Hoffmann P; Kopecký J
    Klin Onkol; 2021; 34(1):73-77. PubMed ID: 33657824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Maio M; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan P; Ibrahim N; Marreaud S; van Akkooi ACJ; Suciu S; Robert C
    N Engl J Med; 2018 May; 378(19):1789-1801. PubMed ID: 29658430
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
    Eroglu Z; Broman KK; Thompson JF; Nijhuis A; Hieken TJ; Kottschade L; Farma JM; Hotz M; Deneve J; Fleming M; Bartlett EK; Sharma A; Dossett L; Hughes T; Gyorki DE; Downs J; Karakousis G; Song Y; Lee A; Berman RS; van Akkooi A; Stahlie E; Han D; Vetto J; Beasley G; Farrow NE; Hui JYC; Moncrieff M; Nobes J; Baecher K; Perez M; Lowe M; Ollila DW; Collichio FA; Bagge RO; Mattsson J; Kroon HM; Chai H; Teras J; Sun J; Carr MJ; Tandon A; Babacan NA; Kim Y; Naqvi M; Zager J; Khushalani NI
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
    Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
    Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
    Eggermont AMM; Dummer R
    Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.